top of page

Search Results

311 results found for "Addex Therapeutics"

Programs (1)

View All

Posts (244)

View All

Other Pages (64)

  • Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer

    Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and

  • Ep 122 with Dr. Nicolas Gilles

    He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic

  • Ep 60 with Dr. Josephine (Pina) Cardarelli

    Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

View All

Events (2)

View All
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
bottom of page